How deadly is Prostate cancer?

Mazal tamattant n cancer tan prostate?

Cancer wan prostate eqqal wa issin n cancer wa ojjaran daɣ addinat daɣ alɣalim s iddikud n 1.276 n addinat eynaynen id iktab nen daɣ awatay wan 2018, eqqal nen 7.1% n addinat fuk wi ilanen cancer daɣ addinat

Iddikud n tamattant n cancer n prostate eqqal deɣ ojjaran s iddikud n 37,005 n tamattant daɣ alɣalim daɣ awatay wan 2018

Hak id ijja awen, iddikud n tamattant izlay hullan s rejion, s West Africa ilan iddikud wis semmus n tamattant n cancer n prostate daɣ alɣalim tolas Nigeria ilan ichaɣib d ekonomi wa maqqoran daɣ rejion ten

Daɣ Nigeria, cancer wan prostate eqqal cancer wa ojjaran tolas wa ojjaran n tamattant i irgazan, s 32.8 n ihukkan d 16.3 n tamattant daɣ 100 000 n irgazan

Awen ojjaran iddikud n iddikud n tamattant daɣ Amrik tan tamasna

Asukni n aśahat daɣ azzaman, ilalan wi ogaran i akayad d akayad, d asukni n isalan d isalan n ihukkan ahanen edag daɣ iddikud n tamattant maqqoran daɣ Nigeria

Daɣ Amerik, cancer tan prostate eqqal s data s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal s eqqal

Iddikud n tamattant n cancer tan prostate eqqal a tijja s afalla ɣur tazwara n awatay wan 1990 mucham har ajjudi eqqal aqqal aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen aqqal nen

Daɣ almaɣna, cancer tan prostate eqqal aṭṭan n tamattant hullan daɣ rejion tan ilan assahat n alxidmat tan ajjotnen d alfayda tan n akayad

Hak id ijja awen, asifham n azzaman d asafar addoben ad issiwid hullan isuj d afanaz n iddikud n tamattant

['Isalan wi illanen']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.

Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.

Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.

Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.

['Asukni: medikal']

['Web site wen eqqal i isalan n teɣare d isalan ɣas tolas war eqqel asiwil n asafar meɣ alxidmat tan n musnat']

['Isalan wi ikfan war addoben ad axdaman i asifham meɣ asafar n aśahat meɣ aśahat tolas wi aramanen asiwil n asafar n awadim ilzam ad aruman asiwil n asafar n awadim']

['Dǎɣ asikin, neural net wa iknanen tirmawen ən assestan, eqal aśohen aśohat dǎɣ alwaq wa id itawan dǎɣ maɗin ən maɗinan. sund, iddikud ən adinat wi atiwasananen as aśohat atiwasanan.']

['Harkuk arha majrad n doctor inek meɣ n awadim n assexat n tazmert n addinat fal aśahat n aśahat. War t-id-t-igdel majrad n aśahat n awadim meɣ azzaman daɣ aśahat fal as harat awa iktabem fal site wen. Afal as ad t-illa aśahat n aśahat n aśahat, asiwel 911 meɣ aru s ehan n aśahat n aśahat wa oharnen daɣ azzaman. War t-illa majrad n aśahat n awadim d aśahat fal site wen meɣ axadam net. BioMedLib meɣ inaxdiman net meɣ awadim wa iknanen fal site wen, war t-illa majrad, iknan meɣ iknan, fal isalan wi dawanen meɣ axadam net']

['Asukni: copyright']

['Digital Millennium Copyright Act wan 1998, 17 U.S.C. § 512 (DMCA) eha almaɣna i kel alxaq n alxaq n alxaq wa allaɣen as isuj win illanen fal Internet ikna alxaq nasan daɣ achareɣa n alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq wan alxaq']

['A fal tazamt s tiditt as isalan meɣ isuj win illanen daɣ asuj n asuj net meɣ alxidmaten iknan alxaq inek n alxaq, addobat ad aɣ-d-tazneḍ (meɣ agent inek) isalan meɣ isuj win ad n-ikkes meɣ ad n-isikkid alxidmat']

['Isalan ilzam ad ittusiknan s eɣaf s email (ikayad edag "Contact" i tansa n email)']

['DMCA t-assirɣas as isalan inek n asiwad n alxaq n alxoriya eha isalan win: (1) almaɣna n alxidmat eha alxaq n alxoriya eqqal harat n asiwad eha alxaq n alxoriya; (2) almaɣna n almaɣna eha alxoriya d isalan ajjotnen ijjan aɣ ad n afhaman almaɣna; (3) isalan n alɣisab inek, ahan tansa, amaṭṭaf n tilifun d tansa n email inek; (4) almaɣna inek n as ilan tumast n alxaq n alxoriya as almaɣna wa s eha alxaq eha alxaq eha alxaq war eha alxaq n alxaq eha alxoriya meɣ amatikki net meɣ s alxidmat n achareɣa fuk']

['(5) almaɣna n awen, iktab daɣ azruf n alkad n tiditt, as isalan win isalan aqqalan tiditt tolas ilan tanaya n as artay alxaqqan win alxakum wi s allaɣen as ikna']

['Dǎɣ awa, əmik ən əmik ən alxaq meɣ awadim ən alxaq ən alxaq meɣ awadim atiwafan ye igi ən alxaq ən alxaq.']

['A fal war t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id-t-id']

['Assahat']

['Ilzam aɣ e-mail s asteqsi meɣ asukni']

How deadly is prostate cancer?

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.

The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.

However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.

In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.

This is more than double the death rate in North America.

Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.

In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.

The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.

Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.

However, early detection and treatment can significantly improve outcomes and reduce mortality rates.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.